PDCD1 and neoplasm: For example, a CDK4/6 inhibitor and anti‐PD‐1 immunotherapy enhanced tumor regression and overall survival rates of tumor‐borne mice [5], and blockade of PD‐L1 potentiated poly‐ADP‐ribose polymerase (PARP) inhibitor anticancer therapies [6].